On Feb 2, medical equipment manufacturer Revvity reported a fourth quarter that beat analyst expectations and issued 2026 guidance that came in above Wall Street forecasts. The company said its diagnostics operations were a primary driver of outperformance, even as academic research spending continued to lag.
Revvity projected adjusted earnings per share for fiscal 2026 of $5.35 to $5.45, compared with analysts' consensus of $5.32, according to data compiled by LSEG. The firm also set a full-year sales range of $2.96 billion to $2.99 billion, topping the $2.93 billion estimate.
CEO Prahlad Singh commented on the quarter, saying, "We finished 2025 on a strong note by delivering results that were solidly ahead of our expectations." The company attributed the resilience of its business in part to improving conditions within the pharmaceutical market and to easing policy uncertainty, factors that have tempered the effect of lower spending from universities and research institutions.
Quarterly performance
For the quarter ended December 28, Revvity reported adjusted earnings of $1.70 per share, compared with analyst estimates of $1.55 per share. Quarterly revenue reached $772.1 million, beating the $761.3 million consensus.
The diagnostics segment stood out with 7% organic growth, generating $390.1 million in revenue versus analyst expectations of $377.7 million. The life sciences unit, which supplies reagents and instruments used in drug discovery, produced $382 million in revenue for the quarter, slightly below the $385.6 million estimate.
Industry peers Danaher and Thermo Fisher Scientific also reported stronger-than-expected fourth-quarter results in the prior week, a backdrop noted by Revvity as indicative of improving trends in portions of the life sciences market.
Outlook and context
Revvity's guidance for fiscal 2026 reflects management's view that diagnostics demand will remain robust despite persistent weakness in academic research funding. The company did not change or add any additional numerical assumptions beyond its published EPS and revenue ranges for 2026.
Investors and market participants should note that Revvity's performance in the quarter was driven by diagnostics growth, while its life sciences business was roughly in line with expectations. The firm highlighted broader market dynamics as a mitigating factor for softer institutional spending.
Data points
- Forecast 2026 adjusted EPS: $5.35 - $5.45 (analysts: $5.32 per LSEG)
- Forecast 2026 revenue: $2.96 billion - $2.99 billion (analysts: $2.93 billion)
- Quarterly adjusted EPS: $1.70 (analysts: $1.55)
- Quarterly revenue: $772.1 million (analysts: $761.3 million)
- Diagnostics revenue (quarter): $390.1 million; organic growth 7% (analysts: $377.7 million)
- Life sciences revenue (quarter): $382 million (analysts: $385.6 million)